Hyperimmune whooping cough serum

McGuinness, Aims C.; Armstrong, Janet G.; Felton, Harriet M.

doi:10.1016/s0022-3476(44)80101-9

Cited by 35 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous workers (McGuinness, Armstrong and Felton, 1944) had shown that large doses of hyperimmune serum were apparently effective in the prevention and treatment of pertussis and suggested that gamma globulin might be found more effective. Cruickshank (1949) reported that, in controlled trials in three residential nurseries, antiserum prepared in rabbits and horses temporarily protected most children inoculated in the incubation period.…”

mentioning

confidence: 99%

Failure of Hyperimmune Gamma Globulin to Prevent Whooping Cough

Morris¹,

McDonald²

1957

Archives of Disease in Childhood

View full text Add to dashboard Cite

mentioning

confidence: 99%

Failure of Hyperimmune Gamma Globulin to Prevent Whooping Cough

Morris¹,

McDonald²

1957

Archives of Disease in Childhood

View full text Add to dashboard Cite

“…The therapeutic role of anti-PT antibodies in patients with established pertussis was not conclusively demonstrated in the past. Pertussis immunoglobulin preparations made from pooled convalescent sera were investigated in trials that resulted in inconclusive efficacy data (5,10,29,33,34,38,58). Subsequent testing has shown that some of these products had low levels of anti-PT IgG antibodies, as seen in Table 1.…”

Section: Discussionmentioning

confidence: 99%

“…In the past pertussis immunoglobulin preparations made from pooled convalescent sera were investigated in trials that resulted in inconclusive efficacy data (5,10,29,33,34,38,58). In a recent Swedish study, a high-titer pertussis immunoglobulin significantly decreased whooping in hospitalized patients with pertussis (23).…”

mentioning

confidence: 99%

Protective Effects of Pertussis Immunoglobulin (P-IGIV) in the Aerosol Challenge Model

Bruss

Siber

1999

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

Pertussis in infants is often severe, resulting in prolonged hospitalization. Treatment is limited to supportive care. Antibiotics do not significantly alter the course of the disease unless administered during the catarrhal phase. Therapies directed at pertussis toxin, a major virulence factor of Bordetella pertussis, may be beneficial. This study uses the aerosol challenge model to further examine the protective effects of P-IGIV, a new intravenous immunoglobulin product, which has high levels of pertussis toxin antibodies. P-IGIV was prepared as a 4% immunoglobulin G (IgG) solution from the pooled donor plasma from donors immunized with inactivated pertussis toxoid. The IgG pertussis toxin antibody concentration in P-IGIV is >7-fold higher than conventional intravenous immunoglobulin products. In the aerosol challenge model, P-IGIV-treated mice exhibited a dose-dependent decrease in mortality when monitored for 28 days postchallenge. P-IGIV in doses of 2,800, 1,400, and 350 mg/kg significantly reduced mortality compared to saline (P < 0.01)- and human IGIV (P < 0.01)-treated controls. The 50% protective dose of pertussis toxin antibodies in P-IGIV was 147 μg/ml. Recovery of weight gain and normalization of leukocyte counts occurred in all P-IGIV-treated groups but did not exhibit dose-dependent characteristics. Even after 7 days of infection, P-IGIV reversed the effects of pertussis in mice. This study provides further evidence that pertussis toxin antibodies not only play a role in passive protection but can also reverse symptoms of established disease in mice. We feel that P-IGIV deserves further evaluation in children hospitalized with severe pertussis.

show abstract

“…Balagtas et al [3] compared the clinical effect of hyperim mune immunoglobulin to pertussis with 20% albumin as placebo on the improve ment of coughing and found no difference. On the other hand Scheinblum and Bullowa [20] and McGuinness et al [13] reported that Human gamma-globulin preparations [12,21,26] for intravenous injection devel oped in recent years have few side effects and quickly establish immunity in the host. They can be used together with antibiotics to prevent or treat serious infections.…”

Section: Introductionmentioning

confidence: 99%

Protective Effects of Human Gamma-Globulin Preparations against Experimental Aerosol Infections of Mice with Bordetella pertussis

Imaizumi¹,

Suzuki²,

Sato³

et al. 1985

Vox Sanguinis

View full text Add to dashboard Cite

The protective effects of three types of pooled human gamma-globulin preparations (intact; GG, S-sulfonated: GGS, and pepsin-treated: GGP) for intravenous use against experimental aerosol infection of mice with Bordetella pertussis have been evaluated. The gamma-globulin preparations GG and GGS showed significant protective activity whereas GGP did not, as evaluated by survival numbers, body weight gains and suppression of leucocytosis. GG and GGS but not GGP also possessed neutralizing activity against leucocytosis-promoting and histamine-sensitizing activities of pertussis toxin (PT). Evaluation of protective activities of GG, GGS and GGP prepared from rabbit gamma-globulin, highly immunized with PT and not containing any anti-F-HA (filamentous haemagglutinin) or agglutinin antibodies, demonstrated that anti-PT-GG and anti-PT-GGS but not anti- PT-GGP protected against experimental infection by B. pertussis. These studies showed that the protective activity was correlated with anti-PT titre but that the Fc portion of the gamma-globulin molecule is necessary for actual protection against whooping cough by B. pertussis.

show abstract

Hyperimmune whooping cough serum

Cited by 35 publications

References 7 publications

Failure of Hyperimmune Gamma Globulin to Prevent Whooping Cough

Failure of Hyperimmune Gamma Globulin to Prevent Whooping Cough

Protective Effects of Pertussis Immunoglobulin (P-IGIV) in the Aerosol Challenge Model

Protective Effects of Human Gamma-Globulin Preparations against Experimental Aerosol Infections of Mice with Bordetella pertussis

Contact Info

Product

Resources

About